Get the Stockscreener App
21.52
1.06%
-0.23
Legend Biotech Corp Adr stock is traded at $21.52, with a volume of 811.97K.
It is down -1.06% in the last 24 hours and up +12.49% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$21.75
Open:
$21.52
24h Volume:
811.97K
Relative Volume:
0.30
Market Cap:
$4.19B
Revenue:
$1.14B
Net Income/Loss:
$-250.98M
P/E Ratio:
-15.82
EPS:
-1.36
Net Cash Flow:
$-251.61M
1W Performance:
+8.25%
1M Performance:
+12.49%
6M Performance:
+20.56%
1Y Performance:
-38.50%
1-Day Range:
$21.41
$21.90
1-Week Range:
$19.71
$22.05
52-Week Range:
$16.24
$37.50
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
21.52 | 4.13B | 1.14B | -250.98M | -251.61M | -1.36 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jan-22-26 | Downgrade | TD Cowen | Buy → Hold |
| Jan-07-26 | Initiated | Oppenheimer | Outperform |
| Oct-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Jun-17-24 | Initiated | Truist | Buy |
| May-24-24 | Reiterated | H.C. Wainwright | Buy |
| May-23-24 | Initiated | Deutsche Bank | Buy |
| Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | Raymond James | Outperform |
| Dec-19-23 | Initiated | Scotiabank | Sector Perform |
| Nov-06-23 | Initiated | Goldman | Buy |
| May-25-23 | Initiated | William Blair | Mkt Perform |
| May-22-23 | Initiated | Daiwa Securities | Buy |
| Mar-29-23 | Initiated | H.C. Wainwright | Buy |
| Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-22 | Initiated | UBS | Buy |
| Nov-02-22 | Initiated | Evercore ISI | Outperform |
| Nov-01-22 | Initiated | Cowen | Outperform |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Mar-15-22 | Initiated | Barclays | Overweight |
| Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-21-21 | Initiated | Piper Sandler | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Jul-01-20 | Initiated | JP Morgan | Overweight |
| Jul-01-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards - Stock Titan
Legend Biotech (NASDAQ:LEGN) Trading Down 5.3% Following Analyst Downgrade - MarketBeat
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns - Investing.com
Oppenheimer downgrades Legend Biotech stock rating on M&A concerns By Investing.com - Investing.com South Africa
Why is Legend Biotech stock sliding today? - Investing.com
Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript - theglobeandmail.com
Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Strong Earnings - MarketBeat
Why is Legend Biotech stock surging today? By Investing.com - Investing.com South Africa
Legend Biotech Q2 2026 slides: first profitable quarter, 50% growth - Investing.com
Legend Biotech Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5% - Investing.com
Why is Legend Biotech stock surging today? - Investing.com
Legend Biotech stock rises 5% on earnings and revenue beat By Investing.com - Investing.com South Africa
Legend Biotech stock rises 5% on earnings and revenue beat - Investing.com
Legend Biotech (NASDAQ:LEGN): What Could Today’s Update Reveal About Cell-Therapy Demand And Manufacturing? - Kalkine Media
Legend Biotech in spotlight: Earnings test Carvykti momentum - Investing.com
1,915,056 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Assenagon Asset Management S.A. - MarketBeat
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sei Investments Co. Buys 221,899 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
Renaissance Technologies LLC Purchases 119,000 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 315,176 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - marketbeat.com
H.C. Wainwright reiterates Buy on Legend Biotech stock, $65 target - Investing.com
Raymond James cuts Legend Biotech stock price target on CEO departure - Investing.com
Why is Legend Biotech stock sliding today? By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down By Investing.com - Investing.com South Africa
Legend Biotech stock falls as CEO Ying Huang steps down - Investing.com
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim By Investing.com - Investing.com South Africa
Legend Biotech CEO Ying Huang steps down, Alan Bash named interim - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns - Investing.com
UBS downgrades Legend Biotech stock rating on competition concerns By Investing.com - Investing.com India
Legend Biotech (NASDAQ:LEGN) Stock Price Up 6.8%Here's Why - MarketBeat
Q4 EPS Estimates for Legend Biotech Cut by HC Wainwright - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO) - The Globe and Mail
H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales - Investing.com
Q2 EPS Estimates for Legend Biotech Boosted by HC Wainwright - MarketBeat
JPMorgan resumes Legend Biotech stock coverage with neutral rating By Investing.com - Investing.com South Africa
JPMorgan resumes Legend Biotech stock coverage with neutral rating - Investing.com
Legend Biotech (LEGN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
LEGNLegend Biotech Corp ADR Options - Finviz
Legend Biotech (LEGN) CEO Ying Huang makes charitable gift of 3,382 shares - Stock Titan
Form 144 Legend Biotech Corp For: 30 June By Investing.com - Investing.com India
Form 4 Legend Biotech Corp For: 29 June - Investing.com India
Legend Biotech CEO Huang Ying sells $82,265 in shares By Investing.com - Investing.com South Africa
Form 4 Legend Biotech Corp For: 29 June By Investing.com - Investing.com South Africa
Legend Biotech CEO Huang Ying sells $82,265 in shares - Investing.com
Form 144 Legend Biotech Corp For: 26 June By Investing.com - Investing.com South Africa
Legend Biotech (LEGN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Legend Biotech Corp. Sponsored ADR Actuals & Estimates (NASDAQ:LEGN) - TradingView
9LB Forecast — Price Target — Prediction for 2027 - TradingView
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching - AOL.com
Form 6K Legend Biotech Corp For: 22 June By Investing.com - Investing.com South Africa
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Legend Biotech Corp Adr Stock (LEGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Huang Ying | Chief Executive Officer |
Jun 25 '26 |
Sale |
14.78 |
5,566 |
82,265 |
241,872 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):